Stockreport

Novartis agrees to acquire a pan-mutant-selective PI3Ka inhibitor, strengthening its breast cancer pipeline [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF The lead asset, SNV4818, currently in a Phase 1/2 clinical study, is designed to selectively target PI3Ka mutations in breast cancer while sparing wild-type PI3Ka, thus [Read more]